(Q45712910)

15 December 2017

title

Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer (English)

1 reference

15 December 2017

1 reference

1 reference

1 reference

9

David R Gandara

1 reference

15 December 2017

Scott D Ramsey

1

1 reference

15 December 2017

Carol M Moinpour

2

1 reference

15 December 2017

Laura C Lovato

3

1 reference

15 December 2017

John J Crowley

4

1 reference

15 December 2017

Patra Grevstad

5

1 reference

15 December 2017

Cary A Presant

6

1 reference

15 December 2017

Saul E Rivkin

7

1 reference

15 December 2017

Karen Kelly

8

1 reference

15 December 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

Journal of the National Cancer Institute

15 December 2017

published in

1 reference

15 December 2017

volume

94

1 reference

15 December 2017

issue

4

1 reference

15 December 2017

page(s)

291-297

1 reference

The burden of illness of cancer: economic cost and quality of life

15 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Linear regression analysis of censored medical costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

On estimating costs for economic evaluation in failure time studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Estimating medical costs from incomplete follow-up data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

On the use of survival analysis techniques to estimate medical care costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

The journal's policy on cost-effectiveness analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Evaluation of conflict of interest in economic analyses of new drugs used in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Reversibility of Long-standing Urinary Tract Obstruction Requiring Long-term Dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Trials and tribulations. Emerging issues in designing economic evaluations alongside clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Economic analyses in clinical trials for cooperative groups: operational considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Incremental costs of enrolling cancer patients in clinical trials: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Cost of care for patients in cancer clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

Economic evaluation of a randomized clinical trial comparing vinorelbine, vinorelbine plus cisplatin, and vindesine plus cisplatin for non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F94.4.291

21 January 2018

Identifiers

DOI

10.1093/JNCI/94.4.291

1 reference

15 December 2017

1 reference